City Therapeutics and Bausch + Lomb have entered into a strategic collaboration focused on the development of an RNA interference-based treatment for geographic atrophy, according to a press release.
City will use its RNA interference (RNAi) engineering technologies to develop a candidate that can be injected intravitreally, while Bausch + Lomb will be responsible for investigational new drug application-enabling studies and clinical development as well as regulatory submissions and commercialization activities.
In addition to an upfront cash payment, City is eligible for contingent payments